GENMAB Inactive Instrument
Genmab Share Price Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,946 DKK | +59.94% |
|
+4.14% | +14.24% |
| 06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
| 06-03 | Transcript : Genmab A/S - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.89B 226B | Sales 2025 * | 23.62B 3.45B 270B | Capitalization | 126B 18.32B 1,433B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 683M 53.42B | Net income 2025 * | 6.61B 965M 75.48B | EV / Sales 2024 * | 5.03 x |
| Net cash position 2024 * | 25.92B 3.78B 296B | Net cash position 2025 * | 32.36B 4.73B 369B | EV / Sales 2025 * | 3.94 x |
| P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
20.6
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +15.55% | 121B | |
| +12.66% | 107B | |
| -2.53% | 24.82B | |
| +0.61% | 22.48B | |
| -42.28% | 16.33B | |
| -18.92% | 15.31B | |
| +6.19% | 14.08B | |
| +28.83% | 11.74B | |
| +80.51% | 9.02B |
